222 related articles for article (PubMed ID: 34519110)
1. Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab.
Al-Shaikhly T; MacDonald JW; Bammler TK; Altman MC; Ayars AG; Petroni DH; Tilles SA; Henderson WR
Clin Exp Allergy; 2021 Dec; 51(12):1648-1652. PubMed ID: 34519110
[No Abstract] [Full Text] [Related]
2. Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria.
Baumann K; Jørgensen AR; Sørensen JA; Zhang DG; Ghazanfar MN; Skov PS; Woetmann A; Vestergaard C; Maurer M; Thomsen SF
Clin Exp Allergy; 2023 Dec; 53(12):1318-1321. PubMed ID: 37771063
[No Abstract] [Full Text] [Related]
3. [HOW PERIPHERAL BASOPHILS IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA ARE CHANGED WITH OMALIZUMAB TREATMENT?].
Oda Y; Washio K; Mizuno M; Imamura S; Nishigori C; Fukunaga A
Arerugi; 2021; 70(9):1196-1199. PubMed ID: 34759084
[No Abstract] [Full Text] [Related]
4. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
MacGlashan D; Saini S; Schroeder JT
J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
Skander D; Allenova A; Maurer M; Kolkhir P
Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
[No Abstract] [Full Text] [Related]
6. A very low number of circulating basophils is predictive of a poor response to omalizumab in chronic spontaneous urticaria.
Rijavec M; Košnik M; Koren A; Kopač P; Šelb J; Vantur R; Kogovšek Ž; Bizjak M; Bajrović N; Zidarn M; Korošec P
Allergy; 2021 Apr; 76(4):1254-1257. PubMed ID: 32876979
[No Abstract] [Full Text] [Related]
7. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
[TBL] [Abstract][Full Text] [Related]
8. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria.
Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709
[TBL] [Abstract][Full Text] [Related]
9. Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria.
Saini SS; Omachi TA; Trzaskoma B; Hulter HN; Rosén K; Sterba PM; Courneya JP; Lackey A; Chen H
J Invest Dermatol; 2017 Apr; 137(4):958-961. PubMed ID: 27939380
[No Abstract] [Full Text] [Related]
10. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
[TBL] [Abstract][Full Text] [Related]
11. Basophil FcɛRI expression is linked to time to omalizumab response in chronic spontaneous urticaria.
Deza G; Bertolín-Colilla M; Sánchez S; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
J Allergy Clin Immunol; 2018 Jun; 141(6):2313-2316.e1. PubMed ID: 29518420
[No Abstract] [Full Text] [Related]
12. Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab.
Cho YT; Fu KT; Yang CW; Chu CY
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):394-395. PubMed ID: 34102302
[No Abstract] [Full Text] [Related]
13. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study.
Cakmak ME
Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494
[TBL] [Abstract][Full Text] [Related]
14. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab.
Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J
J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792
[No Abstract] [Full Text] [Related]
15. Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria?
Thiede RM; Fazel M; MacDonald KM; Abraham I
Expert Opin Pharmacother; 2022 Oct; 23(14):1563-1567. PubMed ID: 36173375
[No Abstract] [Full Text] [Related]
16. The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria.
Maurer M; Kolkhir P; Moñino-Romero S; Metz M
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2390-2391. PubMed ID: 37364668
[No Abstract] [Full Text] [Related]
17. Extracellular vesicle microRNAs as predictors of response to omalizumab in chronic spontaneous urticaria.
Al-Shaikhly T; MacDonald JW; Bammler TK; Altman MC; Ayars AG; Petroni DH; Tilles SA; Henderson WR
Allergy; 2021 Apr; 76(4):1274-1277. PubMed ID: 33314187
[No Abstract] [Full Text] [Related]
18. Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience.
Akdaş E; Adışen E; Öztaş MO; Aksakal AB; İlter N; Gülekon A
An Bras Dermatol; 2023; 98(2):240-242. PubMed ID: 36567165
[No Abstract] [Full Text] [Related]
19. Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.
Ghazanfar MN; Bartko EA; Arildsen NS; Poulsen LK; Jensen BM; Enevold C; Holm JG; Woetmann A; Ødum N; Thomsen SF
Clin Exp Allergy; 2022 May; 52(5):715-718. PubMed ID: 35278253
[No Abstract] [Full Text] [Related]
20. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
